Endocardium-Derived Stem Cell Reprogramming for Cardiovascular Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing induced pluripotent stem cells (iPSCs) for cardiovascular cell therapy face challenges in efficiency, genetic stability, and accessibility of primary cells, with existing cells not meeting ideal criteria for high proliferative potential, ease of isolation, and epigenetic memory.
Innovation Solution
A method involving the introduction of SOX2, c-MYC, OCT4, and KLF4 genes into endocardium-derived adult stem cells from peripheral blood to produce iPSCs, which are then differentiated into endothelial cells, smooth muscle cells, and cardiomyocytes using specific growth factors and media conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If skin fibroblasts are used as primary cells for iPSC production, then ease of access and culture is improved, but proliferative potential and stemness are reduced
Solution Approach 1:
The patent changes the parameter of primary cell type from skin fibroblasts to endocardium-derived adult stem cells (CD34+ cells), which have higher proliferative potential and stemness while still being accessible from peripheral blood. This parameter change resolves the contradiction by finding a cell type that balances ease of access with high productivity.
2Productivity
If cells at a slightly younger stage than adult cells are used, then proliferative potential and stemness are improved, but accessibility and ease of isolation are reduced
Solution Approach 1:
The patent uses CD34+ cells as an intermediary population that exists in peripheral blood and can be easily isolated using standard clinical procedures. These cells serve as a mediator between easily accessible adult cells and the more potent but harder-to-obtain younger stem cells, achieving both accessibility and high proliferative potential.
3Productivity
If iPSCs are produced using a large number of Yamanaka factors, then production efficiency is improved, but genetic modification risk increases
Solution Approach 1:
The patent changes the parameter of primary cell type to endocardium-derived adult stem cells, which inherently express some Yamanaka factors (particularly SOX2 and c-MYC). This reduces the number of exogenous factors needed for reprogramming, thereby maintaining production efficiency while minimizing genetic modification risk and cancer potential.
4Productivity
If primary cells with different epigenetic memory are used, then iPSC production efficiency varies, but differentiation efficiency into target cells is reduced
Solution Approach 1:
The patent applies local quality by selecting primary cells (endocardium-derived CD34+ cells) that have specific epigenetic memory matching the desired target tissue (cardiovascular cells). This ensures both high iPSC production efficiency and high differentiation efficiency into cardiovascular cells, resolving the contradiction between productivity and reliability.
Data Source
AI summary
Disclosed are a method for preparing induced pluripotent stem cells from endocardium-derived adult stem cells isolated from peripheral blood and a method for differentiating induced pluripotent stem cells into cardiovascular cells. The endocardium-derived adult stem cells are primary culture cells for preparing induced pluripotent stem cells, can be readily isolated and cultured only with a small amount of peripheral blood, have a high proliferation property so as to be storable without generic variation, and can rapidly ensure a cell number so as to be usable in cell therapy. The endocardium-derived adult stem cells have sternness, thereby having high preparation efficiency, and are derived from the endocardium so as to have the epigenetic memory of cardiovascular cells, thereby having an advantage of being able to be differentiated, after preparing induced pluripotent stem cells, into cardiovascular cells such as endothelial cells, smooth muscle cells and cardiomyocytes with a high efficiency.